Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06411132 · ClinicalTrials.gov registry record
Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye
A clinical trial, sponsored by Dompé Farmaceutici S.p.A.
- Terminated
- Registry status
- 103
- Enrollment target
NCT06411132: Clinical Trial study, sponsored by Dompé Farmaceutici S.p.A.
NCT06411132 is a clinical trial that was terminated before completion, run by Dompé Farmaceutici S.p.A. The registered enrollment target is 103 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06411132 was terminated before completion, sponsored by Dompé Farmaceutici S.p.A.
- TERMINATED
- Registry status
- 103 participants
- Enrollment target
Study Summary
Primary Objective \- To assess the proportion of patients with Sjögren's dry eye who demonstrate impaired corneal sensitivity. Secondary Objectives * To assess corneal sensitivity via Cochet-Bonnet esthesiometer. * To assess tear secretion via Schirmer I test. * To assess Ocular Pain Assessment Survey (OPAS) questionnaire results.
Primary Outcome
The number and proportion of patients with Sjögren's dry eye who have decreased corneal sensitivity, as determined by Cochet-Bonnet esthesiometer, will be shown with the 95% CI (Wilson method).
Interventions
- OTHER observational study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2024-05-09 |
| Est. Completion | 2025-01-10 |
Why NCT06411132 stopped before completion
NCT06411132 is an observational study that tracks outcomes without assigning an intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which observational study is the first listed.
NCT06411132 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06411132 about?
NCT06411132 is a clinical study titled "Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye". Primary Objective \- To assess the proportion of patients with Sjögren's dry eye who demonstrate impaired corneal sensitivity. Secondary Objectives * To assess corneal sensitivity via Cochet-Bonnet esthesiometer. * To assess tear secretion via Schirmer I test. * To assess Ocular Pain Assessment S...
What is the current status of trial NCT06411132?
This trial is currently terminated. The enrollment target is 103 participants. The study started on 2024-05-09. Estimated completion is 2025-01-10.
What interventions are being tested in trial NCT06411132?
The interventions under investigation include: observational study (OTHER).
Who is sponsoring clinical trial NCT06411132?
This trial is sponsored by Dompé Farmaceutici S.p.A, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI